中国实用神经疾病杂志
中國實用神經疾病雜誌
중국실용신경질병잡지
CHINESE JOURNAL OF PRACTICAL NERVOUS DISEASES
2015年
8期
3-5
,共3页
急性脑梗死%神经保护治疗%单唾液酸四己糖神经节苷脂%依达拉奉
急性腦梗死%神經保護治療%單唾液痠四己糖神經節苷脂%依達拉奉
급성뇌경사%신경보호치료%단타액산사기당신경절감지%의체랍봉
Acute cerebral infarction%Nerve protection treatment%Monosialoteterahexosyl ganglioside%Edaravone
目的：观察单唾液酸四己糖神经节苷脂（GM‐1）联合依达拉奉治疗急性脑梗死（ACI）的临床疗效。方法 ACI患者94例，按照随机数字表法分为观察组和对照组各47例。对照组在常规治疗的基础上加用神经保护剂G M‐1；观察组在对照组的基础上加用依达拉奉；2组疗程均为14 d。观察2组治疗前后神经功能缺损评分（NIHSS评分）、日常生活活动能力指数（Barthel指数）和血清hs‐CRP水平的变化，评价临床疗效。结果治疗前2组NIHSS评分、Barthel指数及血清hs‐CRP水平差异无统计学意义（P＞0．05）；治疗后2组NIHSS评分、Barthel指数及血清hs‐CRP水平均较治疗前明显改善，观察组改善情况明显优于对照组，差异有统计学意义（ P＜0.05）；观察组和对照组的临床总有效率分别为89.36％、72.34％，观察组明显优于对照组，差异有统计学意义（χ2＝2.846，P＜0.05）。结论 GM‐1联合依达拉奉能明显减轻ACI患者炎性反应，改善神经功能和日常生活活动能力，疗效显著，值得临床推广应用。
目的：觀察單唾液痠四己糖神經節苷脂（GM‐1）聯閤依達拉奉治療急性腦梗死（ACI）的臨床療效。方法 ACI患者94例，按照隨機數字錶法分為觀察組和對照組各47例。對照組在常規治療的基礎上加用神經保護劑G M‐1；觀察組在對照組的基礎上加用依達拉奉；2組療程均為14 d。觀察2組治療前後神經功能缺損評分（NIHSS評分）、日常生活活動能力指數（Barthel指數）和血清hs‐CRP水平的變化，評價臨床療效。結果治療前2組NIHSS評分、Barthel指數及血清hs‐CRP水平差異無統計學意義（P＞0．05）；治療後2組NIHSS評分、Barthel指數及血清hs‐CRP水平均較治療前明顯改善，觀察組改善情況明顯優于對照組，差異有統計學意義（ P＜0.05）；觀察組和對照組的臨床總有效率分彆為89.36％、72.34％，觀察組明顯優于對照組，差異有統計學意義（χ2＝2.846，P＜0.05）。結論 GM‐1聯閤依達拉奉能明顯減輕ACI患者炎性反應，改善神經功能和日常生活活動能力，療效顯著，值得臨床推廣應用。
목적：관찰단타액산사기당신경절감지（GM‐1）연합의체랍봉치료급성뇌경사（ACI）적림상료효。방법 ACI환자94례，안조수궤수자표법분위관찰조화대조조각47례。대조조재상규치료적기출상가용신경보호제G M‐1；관찰조재대조조적기출상가용의체랍봉；2조료정균위14 d。관찰2조치료전후신경공능결손평분（NIHSS평분）、일상생활활동능력지수（Barthel지수）화혈청hs‐CRP수평적변화，평개림상료효。결과치료전2조NIHSS평분、Barthel지수급혈청hs‐CRP수평차이무통계학의의（P＞0．05）；치료후2조NIHSS평분、Barthel지수급혈청hs‐CRP수평균교치료전명현개선，관찰조개선정황명현우우대조조，차이유통계학의의（ P＜0.05）；관찰조화대조조적림상총유효솔분별위89.36％、72.34％，관찰조명현우우대조조，차이유통계학의의（χ2＝2.846，P＜0.05）。결론 GM‐1연합의체랍봉능명현감경ACI환자염성반응，개선신경공능화일상생활활동능력，료효현저，치득림상추엄응용。
Objective To observe curative effect of monosialoteterahexosyl ganglioside(GM‐1) combined with edaravone on the treatment of acute cerebral infarction (ACI) .Methods 94 cases with ACI in our hospital from January 2012 to January 2014 were selected and equally divided into observation group and control group (n=47) by random number table method .Be‐sides routine therapy the control group was given neuroprotective agent GM‐1 ;The observation group received GM‐1 and edar‐avone for 14d .NIHSS score ,Barthel index and serum hs‐CRP level of two groups were observed before and after the treat‐ment ,evaluating the clinical efficacy .Results The results showed no statistical differences of the two groups before treatment in NIHSS score ,Barthel index and serum hs‐CRP level (P>0 .05);which were obviously improved after therapy especially in observation group (P<0 .05) ,and total effective rate with 89 .36% in observation group was obviously superior to 72 .34% in control group (χ2 =2 .846 ,P<0 .05) .Conclusion The therapy of GM‐1 and edaravone can obviously alleviate the inflammato‐ry reaction ,improve neural function and life quality of the ACIs ,which should be worthy of clinical application .
